Market Overview

Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene

Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene
Related CELG
5 Biotech Companies To Keep On Your M&A Watchlist For 2019
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You? (Seeking Alpha)

As Tesla Inc (NASDAQ: TSLA) explores an exit from the public markets, one Street analyst on Wednesday said Celgene Corporation (NASDAQ: CELG) could pursue a similar path.

The Rating

RBC Capital analyst Brian Abrahams maintained an Outperform rating on Celgene with a $110 price target.

The Thesis

RBC predicted a go-private path for Celgene’s several months ago, noting the move would provide an immediate premium for shareholders and an attractive longer-term internal rate of return, Abrahams said in a note. (See the analyst's track record here.)

Private status, Abrahams said in the note, would better position the biotech to capture medium-term value from future Revlimid sales that the markets could underappreciate. At the same time, Celgene could cut general and administrative expenses and avoid valuation volatility as it moves beyond Revlimid, he said.

While the significant transaction size was previously expected to prohibit a leveraged buyout, Tesla CEO Elon Musk's statement that his company has secured funding for a similarly sized deal inspired fresh interest in a Celgene transition.

“Though the two companies are in completely different industries, and such funding has not been fully realized (or confirmed available), we believe this does potentially illustrate that performing such a transaction even on such a large company, to help better capture trapped value and/or insulate it from public-markets volatility as it seeks to overcome challenges, may not be completely unrealistic,” Abrahams said.

The analyst said he considers Celgene’s position increasingly less dire given that its underlying business has stabilized and progress has been made on its pipeline. Nonetheless, such a move would be expected to capture value for underappreciated commercial and pipeline products.

Price Action

Celgene shares were trading up 0.25 percent at $91.47 premarket Thursday.

Related Links:

Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives

Photo courtesy of Celgene.

Latest Ratings for CELG

Oct 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jul 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Brian Abrahams RBC CapitalAnalyst Color Price Target Reiteration Top Stories Analyst Ratings Best of Benzinga


Related Articles (CELG + TSLA)

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

ON Semiconductor Faces Potential Multiple Contraction, Morgan Stanley Says In Downgrade

Benzinga's Top Upgrades, Downgrades For August 9, 2018